A Multicenter, Open-label, Single-arm, Study to Evaluate Safety and Tolerability of Repatha in Patients With Homozygous Familial Hypercholesterolemia (HoFH) in India
Phase of Trial: Phase IV
Latest Information Update: 27 Dec 2018
At a glance
- Drugs Evolocumab (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Adverse reactions
- Sponsors Amgen
- 14 Dec 2018 Planned End Date changed from 25 Oct 2020 to 10 Aug 2020.
- 14 Dec 2018 Planned primary completion date changed from 25 Oct 2020 to 10 Aug 2020.
- 31 Aug 2018 Biomarkers information updated